Median Technologies

What Median Technologies does

Median Technologies is a France-based public medical technology company (Euronext Growth Paris: ALMDT) founded in 2002 that operates two integrated business units focused on oncology imaging: iCRO, an imaging contract research organization serving biopharmaceutical sponsors running oncology clinical trials, and eyonis, a portfolio of AI/ML Software as Medical Devices (SaMDs) for early cancer diagnosis. The company has 230+ professionals across 26 countries, with operations in France (Valbonne HQ), the United States (Burlington, MA), and China (Shanghai), and a clinical trial site network spanning 7,000+ sites in 28 countries.

The iCRO business delivers end-to-end imaging services for Phase I–III oncology trials, including core lab imaging, the proprietary iSee Viewer and iSee Portal platforms, AI-powered Imaging Lab analytics (radiomics, predictive biomarkers, treatment response prediction), and a complete radiopharmaceutical imaging solution covering dosimetry and theragnostics. The eyonis platform comprises FDA 510(k)-cleared eyonis LCS (lung cancer screening, the first AI tech-based device specifically cleared by FDA for this indication) and eyonis HCC (hepatocellular carcinoma detection for sub-2cm liver lesions), alongside eyonis IPN for incidental pulmonary nodules. Underlying technology combines proprietary AI/ML, computer vision, and signal processing, validated across 220+ oncology studies, 70+ Phase III trials, 290K+ images QC'd, and 500+ scientific publications, with granted U.S. patent protection.

Revenue is generated primarily through professional services contracts with 80+ biopharma sponsors (iCRO), with a record order backlog of €79.8M as of March 2026. A second revenue stream is emerging from the U.S. and European commercialization of eyonis LCS via Medicare reimbursement under the NT-APC pathway (~$601–$700 per exam), distributed through direct enterprise sales (Median eyonis Inc. subsidiary), a Tempus AI partnership (Tempus Pixel platform), and a second non-exclusive distribution agreement with a leading unnamed U.S. healthcare company. FY2025 reported revenue was €23.5M with operating losses narrowing 28% to €16.3M, and the company has mobilized over €77M in capital across an EIB facility and two equity rounds to fund commercial expansion.

Name

Median Technologies

Legal name

Median Technologies

Website

https://mediantechnologies.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Median Technologies is a French public medical imaging company (Euronext: ALMDT) operating an oncology imaging CRO (iCRO) serving 80+ biopharma clients and a portfolio of FDA-cleared AI Software as Medical Devices (eyonis LCS for lung cancer screening, eyonis HCC for liver cancer).

Ownership category

akta.pro rank

Product category

Medical Imaging Software & Services (Oncology)

NAICS

Software Publishers (5132), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• Medical imaging software
• Oncology clinical trials
• AI cancer diagnosis
• Imaging CRO services
• Software as medical device

Headquarters

HQ city

Valbonne

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. iCRO Imaging Services: Imaging core lab services for oncology clinical trials (phases I-III), including central imaging management, quantitative image analysis, and AI-powered Imaging Lab services for biopharma sponsors. Revenue from service contracts with pharmaceutical and biotech companies. Record order backlog of €79.8M as of March 2026.
2. eyonis LCS Commercialization: Commercial revenue from FDA-cleared eyonis LCS AI-powered lung cancer screening software, sold to U.S. imaging providers through direct enterprise sales and Tempus AI distribution. Medicare reimbursement under NT-APC pathway at approximately $601-$700 per exam. European launch pending CE marking in Q2 2026.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

Median Technologies develops and commercializes AI-powered medical imaging software and services focused on oncology. Its iCRO business unit delivers centralized imaging management, AI-driven imaging biomarker discovery, and radiopharmaceutical imaging solutions to biopharma sponsors running oncology clinical trials across 7,000+ sites in 28 countries. Its eyonis® platform provides AI/ML Software as Medical Devices (SaMDs) for early cancer diagnosis, with eyonis LCS being the first FDA 510(k)-cleared AI device for lung cancer screening detection and diagnosis.

Product overview

Median Technologies operates two distinct business units: iCRO (Imaging CRO) and eyonis®. iCRO provides best-in-class end-to-end clinical trial imaging services for oncology drug development, including core lab imaging, the iSee® Viewer and Portal platforms, Imaging Lab AI-powered analytics, and radiopharmaceutical imaging solutions. The eyonis® platform delivers AI-powered Software as Medical Devices (SaMDs) for early cancer diagnosis, specifically eyonis® LCS for lung cancer screening and incidental pulmonary nodules, and eyonis® HCC for hepatocellular carcinoma. Both units leverage Median's proprietary AI, computer vision, and signal processing technologies.

Differentiator

Problem solved

Functional benefit

Brands

• eyonis LCS: AI-powered Software as Medical Device (SaMD) for lung cancer screening, providing end-to-end CADe/CADx capabilities for detection, localization, and characterization of pulmonary nodules in low-dose CT scans.
• eyonis HCC
• iCRO
• iSee
• Imaging Lab

Products and services

• eyonis® LCS (Lung Cancer Screening) FDA 510(k)-cleared AI-powered Software as Medical Device (SaMD) that detects and characterizes pulmonary nodules in low-dose CT scans, providing malignancy probability scores for lung cancer screening. The first end-to-end CADe/CADx AI device specifically cleared by FDA for lung cancer screening.
• eyonis® IPN (Incidental Pulmonary Nodules)

Quantifiable outcome

• 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value for lung cancer detection in low-dose CT scans
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature6 records

Partnerships

Four partnerships are on record, tiered minor, core and major.

• NYU Langone HealthminorStrategic or Co-development Partner · 1 March 2026Collaboration with NYU Langone Health for advanced molecular profiling in oncology diagnostics. NYU Langone is one of several strategic collaborations Tempus AI announced in 2026; Median is part of this expanded ecosystem.
• Tempus AIcoreChannel Partner/ Reseller/ Distributor · 12 February 2026Non-exclusive distribution agreement for eyonis LCS through Tempus Pixel platform in the U.S. eyonis LCS integrates into Tempus Pixel to enable clinicians to detect, characterize, and risk-rank lung nodules from CT scans. Companies share revenues per partnership terms. This is a key U.S. commercialization channel for Median's flagship AI-powered lung cancer screening product.
• Leading U.S. Healthcare CompanymajorChannel Partner/ Reseller/ Distributor · 8 December 2025Non-exclusive global commercial distribution agreement with a leading U.S. healthcare company to commercialize eyonis LCS in the U.S. and Europe, pending regulatory clearances (FDA 510(k) clearance and CE marking). The partner will leverage its robust infrastructure and broad market reach. Commercialization expected after regulatory approvals.
• Syneos HealthminorStrategic or Co-development Partner · 11 March 2025Joint white paper development on Patient's Body Composition in Oncology Trials, exploring barriers to clinical adoption including clinical evidence, accessibility of assessment tools, usability, and cost-effectiveness. Demonstrates Median's collaborative approach to advancing oncology imaging science.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Optellum: Optellum develops AI-based clinical decision support for lung cancer screening and incidental pulmonary nodule management, directly overlapping with Median's eyonis LCS in target indication, customer base (radiology/imaging centers), and AI imaging modality.
• Lunit: Lunit is a Korean medical AI company with FDA-cleared products for cancer detection including Lunit INSIGHT CXR for chest X-ray and lung nodule AI, comparable to Median's eyonis LCS in oncology imaging AI deployment model and clinical workflow integration.
• Riverain Technologies: Riverain Technologies (acquired by Philips) developed ClearRead CT for lung nodule detection, one of the most direct AI competitors to eyonis LCS in lung CT analysis and image enhancement, with overlapping radiology customer base.
• iCAD: iCAD provides AI-powered cancer detection and therapy planning solutions, including ProFound AI for breast and lung cancer imaging, closely comparable to Median's eyonis portfolio in oncology-focused SaMD commercial model and FDA-cleared imaging AI.
• Clario: Clario (formerly BioClinica/ERT) provides imaging core lab services for clinical trials, directly comparable to Median's iCRO business unit in oncology trial imaging management, central reads, and biopharma customer base.

Broad incumbents

• Aidoc: Aidoc is a leading broad medical imaging AI platform with FDA-cleared AI algorithms across multiple specialties, comparable to Median's eyonis as a regulated imaging AI vendor but with substantially broader indication portfolio and enterprise footprint.

Emerging players

• Quibim: Quibim specializes in radiomics and AI-based imaging biomarkers for oncology and other diseases, comparable to Median's Imaging Lab offering in biopharma R&D imaging intelligence and quantitative image analysis services.
• Perspectum: Perspectum develops AI-enabled medical imaging analysis software for organ-level assessment, overlapping with Median's image-based diagnostic and biomarker capabilities in regulated SaMD deployment to clinical and research settings.
• Annalise.ai: Annalise.ai offers comprehensive AI decision-support across radiology including chest X-ray and CT, comparable to Median's eyonis as a regulated imaging AI vendor targeting radiology workflow and clinical decision support.
• Blackford Analysis: Blackford Analysis provides an AI platform that curates and distributes third-party radiology AI algorithms to clinical sites, comparable to Median's channel distribution model for eyonis LCS through Tempus Pixel and healthcare partner integrations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MEDIANTechno
• YouTubeyoutube.com/user/MEDIANTechnologies
• LinkedInlinkedin.com/company/median-technologies

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds15 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Median Technologies